Cargando…

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

The objective of the present study was to validate the use of intralesional injection of interleukin-2 (IL-2) in patients with skin and soft-tissue melanoma metastases. A total of 24 patients with AJCC stage III or IV melanoma and single or multiple skin and soft-tissue metastases were included. Int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radny, P, Caroli, U M, Bauer, J, Paul, T, Schlegel, C, Eigentler, T K, Weide, B, Schwarz, M, Garbe, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394422/ https://www.ncbi.nlm.nih.gov/pubmed/14583759 http://dx.doi.org/10.1038/sj.bjc.6601320

Ejemplares similares

Determinants of survival in patients with brain metastases from cutaneous melanoma
por: Staudt, M, et al.
Publicado: (2010)

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
por: Weide, B, et al.
Publicado: (2012)

Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma
por: Khoury, Sami, et al.
Publicado: (2021)

Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream
por: Leventhal, Jonathan S., et al.
Publicado: (2016)

Imaging characteristics of cardiac metastases in patients with malignant melanoma
por: Zitzelsberger, Tanja, et al.
Publicado: (2017)

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study
por: Amaral, Teresa, et al.
Publicado: (2020)

Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis
por: Weide, Benjamin, et al.
Publicado: (2013)

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy
por: Meckbach, Diana, et al.
Publicado: (2014)

Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
por: Weide, Benjamin, et al.
Publicado: (2013)

Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma
por: Pflugfelder, Annette, et al.
Publicado: (2011)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
por: Niessner, Heike, et al.
Publicado: (2013)

Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
por: Elsaeßer, Otmar, et al.
Publicado: (2012)

Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour
por: Weide, Benjamin, et al.
Publicado: (2013)

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
por: Gassenmaier, Maximilian, et al.
Publicado: (2021)

Expression of interleukin 10 in human melanoma.
por: Krüger-Krasagakes, S., et al.
Publicado: (1994)

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
por: Thompson, John F., et al.
Publicado: (2014)

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models
por: Eigentler, Thomas, et al.
Publicado: (2016)

Intralesional therapy for advanced melanoma: promise and limitation
por: Agarwala, Sanjiv S.
Publicado: (2015)

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
por: Garbe, Claus, et al.
Publicado: (2011)

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma
por: Meckbach, Diana, et al.
Publicado: (2014)

Current status of intralesional agents in treatment of malignant melanoma
por: Zawit, Misam, et al.
Publicado: (2021)

Topical and Intralesional Immunotherapy for Melanoma In Situ: A Review
por: Martínez-Fernández, Sandra, et al.
Publicado: (2023)

γδ T cell activation may contribute to antitumor immunity stimulated by intralesional BCG immune therapy for cutaneous melanoma metastases
por: Ramos, Romela, et al.
Publicado: (2015)

Intralesional PV‐10 for the treatment of in‐transit melanoma metastases—Results of a prospective, non‐randomized, single center study
por: Read, Tavis A., et al.
Publicado: (2018)

Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas
por: Gassenmaier, Maximilian, et al.
Publicado: (2021)

Development of an Image Analysis-Based Prognosis Score Using Google’s Teachable Machine in Melanoma
por: Forchhammer, Stephan, et al.
Publicado: (2022)

Psychological Distress of Metastatic Melanoma Patients during Treatment with Immune Checkpoint Inhibitors: Results of a Prospective Study
por: Wiens, Lisa, et al.
Publicado: (2021)

Cutaneous metastases of malignant peripheral nerve sheath tumor: Ineffectiveness of intralesional methotrexate
por: Hannah, Claire E., et al.
Publicado: (2018)

Resolution of Metastatic Subungal Eccrine Porocarcinoma Treated with Intralesional Interleukin-2
por: Drohan, Ashley, et al.
Publicado: (2020)

Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma
por: Vidovic, Dejan, et al.
Publicado: (2020)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy
por: Rafei-Shamsabadi, David, et al.
Publicado: (2022)

Neutrophil Extracellular Traps Correlate with Tumor Necrosis and Size in Human Malignant Melanoma Metastases
por: Weide, Lennard Marten, et al.
Publicado: (2023)

Results of a phase II, open‐label, non‐comparative study of intralesional PV‐10 followed by radiotherapy for the treatment of in‐transit or metastatic melanoma
por: Foote, Matthew, et al.
Publicado: (2017)

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
por: Bochem, Jonas, et al.
Publicado: (2019)

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

Diagnostic Accuracy of Electrical Impedance Spectroscopy in Non-melanoma Skin Cancer
por: SARAC, Esra, et al.
Publicado: (2020)

Ipilimumab in a Phase II trial of melanoma patients with brain metastases
por: Margolin, Kim
Publicado: (2012)

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
por: Gaißler, Andrea, et al.
Publicado: (2023)

Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients
por: Posch, C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3p5b3ragfq8pgms1b696qacphj